SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves debt and refinancing risks are driving the discussion, amplified by HSBCs warning that borrowing costs and slower AI demand could weigh on growth. Traders are divided between fears that financing needs threaten the business and the view that strong AI demand and its contracted backlog can support it, with Goldmans more bullish stance adding to the debate.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

Escalating Middle East shipping and energy-infrastructure risks, especially around the Strait of Hormuz and Saudi Arabia, are fueling concern about oil-supply disruptions and drawing attention to USOs crude exposure. Traders are divided between betting that the geopolitical risk premium will sustain oils rise and expecting a sharp pullback if tensions ease or a deal emerges; some also warn the rally is overextended.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is under pressure as traders connect the stocks slide to weakening confidence in Trump ahead of the midterms, alongside concerns about Truth Socials limited business scale, losses, and crypto exposure. Discussion is overwhelmingly bearish, though some traders see a possible short-term bounce and point to the pending TAE fusion deal as a potential diversification opportunity.

USA Rare Earth, Inc. is a domestic supplier of rare earth magnets and heavy rare earth elements. It develops a vertically integrated domestic supply chain for rare earth element magnet production, with a facility in Stillwater and mining rights to the Round Top heavy rare earth and critical minerals deposit in West Texas. The company was founded in May 2019 and is headquartered in Stillwater, OK.

USA Rare Earth Inc. - Ordinary Shares - Class A

USA Rare Earth Inc

A prolonged selloff has focused attention on USAR, with traders pointing to dilution concerns, heavy spending before production scales, and frustration with managements limited communication after the CEO transition. Bulls cite the companys strategic role in a U.S. rare-earth supply chain and government backing, while bears question execution and near-term economics.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

Barclays downgrade of NuScale to Underweight, citing commercial execution risks and delays in firm customer commitmentsparticularly around the proposed TVA projecthas fueled the selloff. Traders are split between concerns that NuScale may struggle to convert its reactor technology into binding projects and bulls who see the decline as overdone given the long-term nuclear-power opportunity.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras steep post-IPO selloff is drawing attention, with traders focused on recurring lockup expirations and insider share sales as potential sources of continued supply; a TD Cowen price-target cut and concerns about OpenAI dependence and competition from Nvidia add to the bearish debate. Some traders see the decline as an oversold buying opportunity, citing the companys AI-chip technology and demand prospects, while others expect more downside until selling pressure eases.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

Salesforces agreement to acquire customer-engagement platform Braze is drawing attention, with traders weighing the deals potential to strengthen Marketing Cloud and its AI strategy against concerns about the cost and pressure on CRM shares. Some also frame the deal as part of Salesforces broader push to expand its enterprise software offerings.

General Motors Co. engages in the designing, manufacturing, and selling of trucks, crossovers, cars, and automobile parts, and in providing software-enabled services and subscriptions. It operates through the following segments: GMNA, GMI, Cruise, and GM Financial. The company was founded by William C. Durant on September 16, 1908 and is headquartered in Detroit, MI.

General Motors Company

GMs quarterly earnings and revenue beat expectations, and the company authorized a large share buyback, but shares fell as traders focused on a narrowed full-year profit outlook that offered no improvement at its midpoint and weaker U.S. sales. Some see the buyback and cash flow as supportive, while others argue the cautious outlook outweighed the strong quarter.

RTX Corp. is an aerospace and defense company, which engages in the provision of aerospace and defense systems and services for commercial, military, and government customers. It operates through the following segments: Collins Aerospace Systems (Collins), Pratt and Whitney, Raytheon Intelligence and Space (RIS), and Raytheon Missiles and Defense (RMD). The Collins segment manufactures and sells aero structures, avionics, interiors, mechanical systems, mission systems, and power controls. The Pratt and Whitney segment includes the design and manufacture of aircraft engines and auxiliary power systems for commercial, military, and business aircraft. The RIS segment is involved in the development of sensors, training, and cyber and software solutions. The RMD segment offers end-to-end solutions to detect, track, and engage threats. The company was founded in 1922 and is headquartered in Arlington, VA.

RTX Corp

Raytheon Technologies Corporation

RTX is drawing attention after a broad quarterly earnings beat and a higher full-year outlook, backed by record backlog and demand across defense and aerospace. Traders are bullish on the results but debate why the share-price reaction has been muted.

GE Aerospace is an American aircraft company, which engages in the provision of jet and turboprop engines, as well as integrated systems for commercial, military, business, and general aviation aircraft. The firm's portfolio of brands includes Avio Aero, Unison, GE Additive, and Dowty Propellers. It operates through the following segments: Commercial Engines and Services, Defense and Propulsion Technologies, and Corporate and Other. The Commercial Engines and Services segment is involved in the design, development, manufacturing, and servicing of jet engines for commercial airframes, as well as business aviation and aeroderivative applications. The Defense and Propulsion Technologies segment offers defense engines and critical aircraft systems. The Corporate and Other segment relates to corporate functions and operations costs. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Evendale, OH.

GE Aerospace

GEs quarterly results beat expectations and management raised its outlook, but shares fell as traders focused on rising costs, weaker free cash flow, and a loss in its insurance business. The reaction reflects a debate between strong aerospace demand and order growth versus pressure on margins and cash generation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Full Transcript: GoodRx Holdings Q2 2026 Earnings Call

GoodRx Holdings (NASDAQ:GDRX) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call.
Benzinga APIs provide real-time access to earnings call transcripts andread more...

From Kids to Canines: GoodRx Launches Companion Family Plan to Bring Healthcare Savings to the Whole Household

GoodRx (Nasdaq: GDRX), the trusted platform for prescription access and affordability in the U.S., today launched the GoodRx Companion Family Plan, expanding its everyday healthcare subscription to the entire family, including pets. As widening coverage gaps and rising out-of-pocket costs leave...

HIMS Stock More Than Doubled in 6 Months: What's Driving the Rally?

Hims & Hers' rally is fueled by branded weight-loss growth, international expansion, AI efficiencies and a broader specialty portfolio.

GoodRx Holdings, Inc. Q2 Profit Falls

(RTTNews) - GoodRx Holdings, Inc. (GDRX) announced earnings for second quarter that Drops, from last year...

GoodRx Holdings, Inc. (GDRX) Q2 Earnings Match Estimates

GoodRx (GDRX) delivered earnings and revenue surprises of 0.00% and +3.92%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

GoodRx (GDRX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for GoodRx (GDRX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

GoodRx Reports Second Quarter 2026 Results

GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," GoodRx, or the Company), the leading platform for medication savings in the U.S., has released its financial results for the second quarter of 2026. Second Quarter 2026 Highlights Revenue of $200.4 million Net income of $8.5 million; Net...

Ardent Health, Inc. (ARDT) Q2 Earnings Lag Estimates

Ardent Health, Inc. (ARDT) delivered earnings and revenue surprises of -29.41% and +1.96%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Labcorp (LH): Can Its 3.4% Jump Turn into More Strength?

Labcorp (LH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

GoodRx Announces Date for Second Quarter 2026 Earnings Release and Conference Call

GoodRx Holdings, Inc. (Nasdaq: GDRX) (GoodRx or the Company), the leading platform for prescription savings in the U.S., today announced it will release its second quarter 2026 financial results after U.S. markets close on Wednesday, August 5, 2026. GoodRx management will also hold a conference...

GoodRx Holdings, Inc. engages in the business of a consumer-focused digital healthcare platform. It offers consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. The company was founded by Trevor Bezdek and Douglas Joseph Hirsch in September 2011 and is headquartered in Santa Monica, CA.

GoodRx Holdings Inc - Ordinary Shares - Class A

Hims & Hers Enters 2026 On Solid Ground — Stock Rises Even After Novo Nordisk Leaves It Off Wegovy Partner List

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Hims shares logged their best session in a month and added after-hours gains.</li><li>Novo expanded oral Wegovy access, while Citi kept a ‘Sell’ rating on Hims.</li><li>Hims continues to broaden its platform through international expansion and new services.</li></ul>Hims &amp; Hers Health Inc. shares posted their strongest session in a month on Monday and added another 0.7% in after-hours trading, with both trading days so far this year ending higher.The move came despite a cautious note from Citi, which said Novo Nordisk’s latest Wegovy announcement could pressure Hims’ GLP-1 business in 2026. Citi kept a 'Sell' rating on the stock with a $30 price target.<h2 class="st-heading-2">Novo’s Oral Wegovy Move Leaves HIMS On The Sidelines</h2>Novo Nordisk said on Monday that its oral Wegovy pill is now broadly available in the U.S., with pricing starting at $149 a month for specific doses and higher prices for larger doses later in 2026. Novo also said commercially insured patients could access the pill for as low as $25 per month.Citi said Hims was again left off Novo’s list of partners, which includes CVS Health, Costco, LifeMD and GoodRx. The firm said this likely reflects disagreements between Novo and Hims around Hims’ compounded semaglutide strategy, and added that the broader rollout of Wegovy pills could put pressure on Hims’ GLP-1 business this year.<h2 class="st-heading-2">Broader Growth Drivers Remain in Focus</h2>Hims &amp; Hers Health has spent recent months expanding its platform beyond weight loss through geographic expansion, new product launches and acquisitions. In December, the company announced the expansion of its Weight Loss Program to the UK, including the official launch of the Hers platform for eligible women, offering access to weight-management care following assessments by GMC-registered doctors. The UK offering includes branded GLP-1 options and oral non-prescription treatments.Hims has also entered Canada following the completion of its acquisition of Livewell, a Canadian digital health platform. Additionally, the company said it will acquire YourBio Health, which develops capillary whole blood sampling technology, including the TAP device that uses bladeless microneedles.&nbsp;Separately, Hims launched its Labs in-depth testing experience, which provides customers with blood-based biomarker testing and doctor-developed action plans across areas such as heart health, metabolism, hormones and inflammation. The company said it plans to expand the Labs offering over time to include additional biomarker tests, at-home testing devices and advanced diagnostics.In December, Barclays initiated coverage of Hims with an ‘Overweight’ rating and a $48 price target, noting that expectations for the business had become more reasonable and pointing to the addition of other growth drivers for FY26.<h2 class="st-heading-2">Investors Look Beyond Near-Term GLP-1 Pressure</h2>Competition in the GLP-1 weight-loss space continues to broaden. Novo Nordisk and Eli Lilly dominate the market with Wegovy and Zepbound, respectively, and Lilly’s injectable Zepbound has been shown in a head-to-head study to deliver greater average weight loss than Wegovy. Novo has since launched the first FDA-approved oral GLP-1 for weight loss, while Lilly is advancing its own oral candidate, orforglipron, which is under regulatory review. Both companies have also cut cash-pay prices for lower doses as access expands beyond insurance-covered channels.Beyond Novo and Lilly, other drugmakers are developing next-generation obesity treatments, including Lilly’s retatrutide and Novo’s CagriSema, while additional companies such as Pfizer and Structure Therapeutics are working on oral weight-loss drugs.&nbsp;<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment was ‘bullish’ amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/hims_ss_png_55bef6044e.webp" alt="hims ss.png" width="972" height="144"><figcaption>HIMS sentiment and message volume as of January 5| Source: Stocktwits</figcaption></figure>One user said, “Injections vs pills for weight loss will be a big deal. Who wouldnt rather take a pill. HIMS needs to get Novo deal or somehow get access to sell the pill, otherwise their weight loss related revenue will tank”<stembedurl>https://stocktwits.com/Matril/message/640906333</stembedurl>Another user said that with GLP-1 pills now available through large retailers such as Costco, the downside risks are already reflected in the stock price, and added that future catalysts could include share buybacks and increased trading activity.<stembedurl>https://stocktwits.com/ros_/message/640880655</stembedurl><a href="https://stocktwits.com/symbol/HIMS">Hims’ stock</a> has risen 30% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Hims & Hers Health in front of a screen showing the company's stock market chart. (Photo illustration by Cheng Xin/Getty Images)

The development comes as attention remains on Hims’ longer-term business expansion initiatives.

Costco Wholesale Corp

CVS Health Corp

GoodRx Holdings Inc

Structure Therapeutics Inc - ADR

Hims & Hers Health Inc

LifeMD Inc

Lilly(Eli) & Co

Novo Nordisk A/S

Pfizer Inc

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$3.37
Prev Close	$3.36
Open	$3.36
Dividend Yield	0.00%
50-Day Moving Average	$3.45
Beta	1.26
Avg. Volume	924,826.46
PE Ratio	71.55

52-Week High	$4.05
52-Week Low	$1.77
Market Capitalization	$1.15B
EPS (Annual)	$0.0853
Price to Book	1.77
Revenue Per Employee	$1.14M

Feed

News

Sentiment

Earnings

Fundamentals

Info

GDRX Fundamentals